1. Delayed False Elevation of Circulating Tacrolimus Concentrations after Cord Blood Transplantation in a Patient with Myelodysplastic Syndrome
- Author
-
Yoshiko Matsuhashi, Tadashi Hirose, Kaoru Tohyama, Kiyohito Hayashi, Katsunori Kohguchi, Takashi Sugihara, Taizo Tasaka, Hideho Wada, and Satoko Furukawa
- Subjects
Male ,medicine.medical_specialty ,Globulin ,Graft vs Host Disease ,Cord Blood Stem Cell Transplantation ,Disease ,Gastroenterology ,Tacrolimus ,Internal medicine ,Internal Medicine ,Humans ,Medicine ,False Positive Reactions ,Cord blood transplantation ,Immunoassay ,Autoimmune disease ,biology ,medicine.diagnostic_test ,business.industry ,Behcet Syndrome ,General Medicine ,Middle Aged ,medicine.disease ,Myelodysplastic Syndromes ,Immunology ,Cyclosporine ,biology.protein ,Antibody ,business ,Immunosuppressive Agents - Abstract
We herein describe the case of a 60-year-old man with a history of Behcet's disease and myelodysplastic syndrome who received cord blood transplantation (CBT). The patient was given anti-thymocyte globulin conditioning and tacrolimus to prevent graft-versus-host disease. Two months after CBT, his blood Tac concentration measured by an antibody-conjugated magnetic immunoassay (ACMIA) was found to have increased >4-fold, even after the Tac treatment was stopped. This false response was caused by the interference of endogenous heterophilic antibodies with ACMIA. Therefore, physicians must be aware of possible false ACMIA results for patients with a history of autoimmune disease and/or treated by xenogeneic antibody therapy.
- Published
- 2014
- Full Text
- View/download PDF